These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35988891)

  • 21. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.
    Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J
    Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circ_0081143 Contributes to Gastric Cancer Malignant Development and Doxorubicin Resistance by Elevating the Expression of YES1 by Targeting mziR-129-2-3p.
    Ou W; Lin L; Chen R; Xu Q; Zhou C
    Gut Liver; 2022 Nov; 16(6):861-874. PubMed ID: 35686503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis.
    Mao L; Yuan W; Cai K; Lai C; Huang C; Xu Y; Zhong S; Yang C; Wang R; Zeng P; Huang H; Chen Z; Chen Z
    Oncogene; 2021 May; 40(20):3610-3623. PubMed ID: 33941853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.
    Liu Y; Li Y; Liu S; Adeegbe DO; Christensen CL; Quinn MM; Dries R; Han S; Buczkowski K; Wang X; Chen T; Gao P; Zhang H; Li F; Hammerman PS; Bradner JE; Quayle SN; Wong KK
    Cancer Res; 2018 Jul; 78(13):3709-3717. PubMed ID: 29760044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic strategy using novel RET/YES1 dual-target inhibitor in lung cancer.
    Choi YJ; Choi M; Park J; Park M; Kim MJ; Lee JS; Oh SJ; Lee YJ; Shim WS; Kim JW; Kim MJ; Kim YC; Kang KW
    Biomed Pharmacother; 2024 Feb; 171():116124. PubMed ID: 38198957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer.
    Ciampricotti M; Karakousi T; Richards AL; Quintanal-Villalonga À; Karatza A; Caeser R; Costa EA; Allaj V; Manoj P; Spainhower KB; Kombak FE; Sanchez-Rivera FJ; Jaspers JE; Zavitsanou AM; Maddalo D; Ventura A; Rideout WM; Akama-Garren EH; Jacks T; Donoghue MTA; Sen T; Oliver TG; Poirier JT; Papagiannakopoulos T; Rudin CM
    Cancer Discov; 2021 Dec; 11(12):3214-3229. PubMed ID: 34344693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in Small-Cell Lung Cancer (SCLC) Translational Research.
    Drapkin BJ; Rudin CM
    Cold Spring Harb Perspect Med; 2021 Apr; 11(4):. PubMed ID: 32513672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of DHODH as a therapeutic target in small cell lung cancer.
    Li L; Ng SR; Colón CI; Drapkin BJ; Hsu PP; Li Z; Nabel CS; Lewis CA; Romero R; Mercer KL; Bhutkar A; Phat S; Myers DT; Muzumdar MD; Westcott PMK; Beytagh MC; Farago AF; Vander Heiden MG; Dyson NJ; Jacks T
    Sci Transl Med; 2019 Nov; 11(517):. PubMed ID: 31694929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.
    Jahchan NS; Lim JS; Bola B; Morris K; Seitz G; Tran KQ; Xu L; Trapani F; Morrow CJ; Cristea S; Coles GL; Yang D; Vaka D; Kareta MS; George J; Mazur PK; Nguyen T; Anderson WC; Dylla SJ; Blackhall F; Peifer M; Dive C; Sage J
    Cell Rep; 2016 Jul; 16(3):644-56. PubMed ID: 27373157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
    Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
    Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of lncRNA KCNQ1OT1 Improves Apoptosis and Chemotherapy Drug Response in Small Cell Lung Cancer by TGF-β1 Mediated Epithelial-to-Mesenchymal Transition.
    Li D; Tong Q; Lian Y; Chen Z; Zhu Y; Huang W; Wen Y; Wang Q; Liang S; Li M; Zheng J; Liu Z; Liu H; Guo L
    Cancer Res Treat; 2021 Oct; 53(4):1042-1056. PubMed ID: 33705625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circ-ZNF124 downregulation inhibits non-small cell lung cancer progression partly by inactivating the Wnt/β-catenin signaling pathway via mediating the miR-498/YES1 axis.
    Gao F; Jia L; Han J; Wang Y; Luo W; Zeng Y
    Anticancer Drugs; 2021 Mar; 32(3):257-268. PubMed ID: 33186139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer.
    Tanaka N; Toyooka S; Soh J; Kubo T; Yamamoto H; Maki Y; Muraoka T; Shien K; Furukawa M; Ueno T; Asano H; Tsukuda K; Aoe K; Miyoshi S
    Lung Cancer; 2012 Apr; 76(1):32-8. PubMed ID: 22047961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
    Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
    Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
    Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
    Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
    Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
    Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation.
    Tokgun O; Tokgun PE; Inci K; Akca H
    Anticancer Agents Med Chem; 2020; 20(17):2074-2081. PubMed ID: 32698750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer.
    Pandey M; Mukhopadhyay A; Sharawat SK; Kumar S
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188552. PubMed ID: 33892053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.